This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 30.77% and 8.51%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Medtronic (MDT) Report Volume Improvement in Q2 Earnings?
by Zacks Equity Research
Medtronic (MDT) is hopeful about a sequential improvement of about 8% in the fiscal second quarter, which implies a 9% year-over-year decline.
Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line
by Zacks Equity Research
Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.
Medtronic (MDT) Integrates InPen With Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) strategic acquisition of Companion Medical strengthens the company's data science and AI capabilities.
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.
Aurora Cannabis (ACB) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal first-quarter results are likely to reflect solid prospects in the Canadian market.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
The Zacks Analyst Blog Highlights: Alibaba, Berkshire Hathaway, Coca-Cola, Medtronic and Fiserv
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Berkshire Hathaway, Coca-Cola, Medtronic and Fiserv
Top Research Reports for Alibaba, Berkshire Hathaway & Coca-Cola
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Berkshire Hathaway (BRK.B) and Coca-Cola Company (KO).
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings
by Sriparna Ghosal
These three MedTech stocks are expected to grow post their Q3 earnings release.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio
by Zacks Equity Research
Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
The Zacks Analyst Blog Highlights: Amazon, Medtronic, CME Group, Intuitive Surgical and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Medtronic, CME Group, Intuitive Surgical and Duke Energy
Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Top Research Reports for Amazon, Medtronic & CME
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Medtronic (MDT) and CME Group (CME).
Medtronic Wins Neuromodulation Patent Dispute Against Axonics
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Medtronic TYRX Driveline Gets FDA's Breakthrough Designation
by Zacks Equity Research
This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Medtronic's (MDT) TYRX Envelope Study Results Encouraging
by Zacks Equity Research
Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.